• Penumbra has initiated the FORWARD study, an international, real-world, prospective trial of up to 250 patients across about 40 sites, evaluating safety and efficacy of its RED reperfusion catheter portfolio, including the recently cleared THUNDERBOLT CAVT system, for treating acute ischemic stroke with distal M2 occlusions.
• An interesting aspect of FORWARD is that it compares mechanical thrombectomy plus medical management against medical management alone in M2 occlusions, generating head-to-head data that could influence how clinicians choose between advanced catheter-based intervention and drug-only therapy in this complex stroke subgroup.
• We’ll now examine how the FORWARD real-world study of THUNDERBOLT and RED catheters may influence Penumbra’s broader investment narrative.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Penumbra Investment Narrative Recap

To own Penumbra, you have to believe in long term demand for minimally invasive stroke and vascular interventions, supported by strong clinical data and real world outcomes. The FORWARD study reinforces this data engine around THUNDERBOLT and RED catheters, but does not change the near term focus on the Boston Scientific acquisition as the key catalyst, nor does it reduce core risks around competition, pricing pressure and dependence on a concentrated neurovascular portfolio.

Among recent developments, the FDA clearance of THUNDERBOLT in June 2026 looks most connected to FORWARD, since the study effectively becomes a real world extension of that clearance. Together, clearance and FORWARD may strengthen the clinical and commercial case for Penumbra’s CAVT platforms in stroke, complementing earlier STORM PE data in pulmonary embolism and potentially shaping how the combined Boston Scientific and Penumbra portfolio competes against other thrombectomy approaches.

Yet, while FORWARD may deepen the clinical moat, investors should still be aware of how intensifying competition could pressure pricing and margins in ways that...

Penumbra's narrative projects $2.1 billion revenue and $311.7 million earnings by 2029.

Uncover how Penumbra's forecasts yield a $363.36 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were only assuming about US$1.9 billion of revenue and US$244.7 million of earnings by 2028, so compared with their concern that Thunderbolt and Lightning Flash 3.0 adoption could be slower than hoped, the new FORWARD stroke study might either ease or reinforce those doubts, and you should recognize how far apart these views can be before deciding which story you find more convincing.

Explore 2 other fair value estimates on Penumbra - why the stock might be worth as much as 14% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Penumbra research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Penumbra research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Penumbra's overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.